Compare Moderna, Inc. (MRNA) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while abrdn Physical Palladium Shares ETF trades at $20.77 (market cap $586.03M). The key difference: Moderna, Inc. is far larger — about 134.2× abrdn Physical Palladium Shares ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| MRNA | PALL | |
|---|---|---|
Market Cap | $78.65B | $586.03M |
Volume | 37,373,437 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $203.46 | $37.18 |
52-Week Low | $22.36 | $20.30 |
Typical Hold Time | 59 Days | 33 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
PALL trades at $20.77, up 2.32% today, but technical indicators show a bearish trend with moving averages unanimously negative. The ETF faces fundamental data gaps in valuation and profitability metrics. Recent news highlights palladium's underperformance versus other precious metals, with some analysts seeing current price weakness as a buying opportunity given supply risks and industrial demand potential.
The outlook remains cautious with strong bearish technical signals offset by potential catch-up trade opportunities. Key risks include commodity price volatility and industrial demand fluctuations, while potential upside depends on palladium market dynamics reversing recent weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
